問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Infectious Disease

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

更新時間：2024-06-13

曾慧恩Tzeng, Huey-En
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • tzenghueyen@gmail.com

Recruiting Trial

44Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾慧恩

List

71Cases

2022-01-01 - 2024-08-08

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2021-03-01 - 2023-05-31

Phase I

A Phase Ⅰ Study of the Safety, Tolerability, Pharmacokinetics Profile, and Preliminary Efficacy of TT-00434 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    TT-00434

Participate Sites
3Sites

Not yet recruiting2Sites

Terminated1Sites

2019-01-11 - 2024-12-31

Phase II

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Zanubrutinib (BGB-3111)

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2018-03-10 - 2021-06-30

Phase I

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors

  • Test Drug

    ABBV-368

Participate Sites
5Sites

Terminated5Sites

李欣倫
Taipei Medical University Hospital

Division of Radiation Therapy

2021-12-01 - 2022-12-12

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2014-11-01 - 2022-02-28

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma

  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    nab-Paclitaxel

Participate Sites
6Sites

Terminated6Sites

2015-05-01 - 2023-04-24

Phase III

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Ixazomib (MLN9708)

Participate Sites
4Sites

Terminated3Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2020-01-01 - 2026-12-31

Phase I/II

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations

  • Condition/Disease

    Advanced or metastatic malignancies

  • Test Drug

    Repotrectinib

Participate Sites
2Sites

Recruiting2Sites

2018-04-19 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)

  • Condition/Disease

    Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Terminated7Sites

2017-09-30 - 2022-09-30

Phase I

A Phase 1 Study of HLX06, a Fully Human Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients with Advanced Solid Tumors Refractory to Standard Therapy

  • Condition/Disease

    Patients with Advanced Solid Tumors Refractory to Standard Therapy

  • Test Drug

    HLX06

Participate Sites
3Sites

Terminated3Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB